VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients

Summary

Circulating cells of several lineages are thought to participate in angiogenesis and tumor growth. Experimental studies in tumorbearing mice have pointed to the potential importance of VEGFresponding circulating (endothelial) progenitor cells in tumor growth.We have studied circulating CD31- and/or CD34-positive cell populations with a low to moderateVEGFR2 expression in human volunteers and cancer patients. We recognized four cell populations, which were further characterized by their content of major hematopoetic progenitor, monocytic, endothelial and platelet markers. After establishing the test-retest stability of the measurements in nine patients, we determined the frequencies of the various cell populations in a group of 20 volunteers and 14 cancer patients.Two populations were markedly increased in cancer patients. Small CD45^neg /CD34^bright/VEGFR2+ cells amounted to 12 and 64 cells/ml (P<0.0001), respectively, and 246/ml and 578/ml VEGFR2+/CD45^bright (/CD14+) monocytic cells were present in controls and cancer patients, respectively (P=0.017). A third population of CD45^dim/CD34^bright/ VEGFR2^low cells amounted to 25 and 30 cells/ml (P=0.38).Unexpectedly, a population of mainly anucleated CD45^low/CD31^bright/ CD41^bright cells was present in numbers of 9,076 and 16,697/ml (P=0.04) in volunteers and cancer patients, which contained a VEGFR2^low (compared to IgG isotype control) expressing population amounting to 1,142 and 1,642 cells/ml (P=0.12). This fourth population probably reflects large platelets. The role of the herein identified VEGFR2⁺ circulating cell populations deserve further investigation in cancer patients treated with VEGF(R)-targeted therapies. Quantification of such cell populations in the blood of tumor patients may be valuable to monitor the efficacy of anti-angiogenic treatment.

Keywords

Circulating progenitor cells - circulating endothelial cells - VEGFR2 - KDR - CD31 - peripheral blood - large platelets - cancer

• References

• 1 Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-712.
• 2 Asahara T, Takahashi T, Masuda H. et al. VEGF contributes to postnatal neovascularization by mobilizing bone-marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964-3972.
• 3 Sebzda E, Hibbard C, Sweeney S. et al. Syk and Slp-76 mutant mice reveal a cell-autonomous hematopoetic cell contribution to vascular development. Develop Cell 2006; 11: 349-361.
• 4 Li S, Zhou B, Han ZC. Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34+ and CD34– mononuclear cells. Thromb Haemost 2006; 95: 301-311.
• 5 Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005; 106: 1525-1531.
• 6 Conejo-Garcia JR, Buckanovich RJ, Benencia F. et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005; 105: 679-681.
• 7 De Palma M, Venneri MA, Galli R, Sergi LS, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-226.
• 8 Hristov M, Erl W, Linder S. et al. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood 2004; 104: 2761-2766.
• 9 Shaked Y, Bertolini F, Man S. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7: 101-111.
• 10 Beaudry P, Force J, Naumov GN. et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 3514-3522.
• 11 Jain RK, Duda DG. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003; 3: 515-516.
• 12 Willett CG, Boucher Y, di Tomaso E. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
• 13 Willett CG, Boucher Y, Duda DG. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136-8139.
• 14 Mancuso P, Colleoni M, Calleri A. et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452-459.
• 15 Bagley RG, Walter-Yohrling J, Cao X. et al. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 2003; 63: 5866-5873.
• 16 Brennan RL. Generalizability theory. Springer; New York: 2001: 538.
• 17 Mancuso P, Burlini A, Pruneri G. et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661.
• 18 Massa M, Rosti V, Ferrario M. et al. Increased circulating hematopoetic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005; 105: 199-206.
• 19 Kondo T, Hayashi M, Takeshita K. et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004; 24: 1442-1447.
• 20 Jain RK, Duda DG, Clark JW. et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
• 21 Faivre S, Delbaldo C, Vera K. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
• 22 Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Update 2005; 8: 59-74.
• 23 Hansma AHG, Broxterman HJ, van der Horst I. et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase 1 and pharmacokinetic study in patients with advanced cancer. Ann Oncol 2005; 16: 1695-1701.
• 24 Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Update 2005; 8: 183-197.
• 25 Capillo M, Mancuso P, Gobbi A. et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003; 9: 377-382.
• 26 Elsheikh E, Uzunel M, He Z. et al. Only a specific subset of human peripheral-blood monocytes has endothelial- like functional capacity. Blood 2005; 106: 2347-2355.
• 27 Romagnani P, Annunziato F, Liotta F. et al. CD14+ CD34^low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 2005; 97: 314-322.
• 28 Friedrich EB, Walenta K, Scharlau J. et al. CD34- /CD133⁺ /VEGFR2⁺ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006; 98: e20-e25.
• 29 Blann AD, Pretorius A. Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins?. Atherosclerosis 2006; 188: 12-18.
• 30 Duda DG, Cohen KS, di Tomaso E. et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006; 24: 1449-1453.
• 31 Khan SS, Solomon MA, McCoy Jr. JP. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytom part B-Clin Cytom 2005; 64B: 1-8.
• 32 Blann AD, Woywodt A, Bertolini F. et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 228-235.
• 33 Woywodt A, Schroeder M, Gwinner W. et al. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003; 76: 1-4.
• 34 Nakatani K, Takeshita S, Tsujimoto H. et al. Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 2003; 131: 536-540.
• 35 Makin AJ, Blann AD, Chung NA. et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J 2004; 25: 371-376.
• 36 Del Papa N, Colombo G, Fracchiolla N. et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004; 50: 1296-1304.
• 37 Woywodt A, Blann AD, Kirsch T. et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4: 671-677.
• 38 Segal MS, Bihorac A, Koc M. Circulating endothelial cells: tea leaves for renal disease. Am J Physiol Renal Physiol 2002; 283: F11-F19.
• 39 Yee KWL, Hagey A, Verstovsek S. et al. Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005; 11: 6615-6624.
• 40 Strijbos MH, Kraan J, den Bakker MA. et al. Cells meeting our immunophenotypic criteria of endothelial cells (CMOIC) are large platelets. Cytometry part B-Clinical Cytometry 2007; 72B: 86-93.
• 41 Selheim F, Holmsen H, Vassbotn FS. Identification of functional VEGF receptors on human platelets. FEBS Letters 2002; 512: 107-110.
• 42 Casella I, Feccia T, Chelucci C. et al. Autrocrineparacrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101: 1316-1323.
• 43 Delorme B, Basire A, Gentile C. et al. Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells. Thromb Haemost 2005; 94: 1270-1279.
• 44 Goon PKY, Boos CJ, Stonelake PS. et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 2006; 96: 45-52.
• 45 Farace F, Soria J-C, Massard C. et al. Circulating endothelial cells and progenitor cells during phase I trial combining vascular disrupting agent and chemotherapy in slid tumors. 2007. Proc. 5th Int. Symp. on Targeted Anticancer Therapies. Amsterdam, March 8–10, 2007. Abstract O205.
• 46 Rowand JL, Martin G, Doyle GV. et al Endothelial cell in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry (Part A) 2007; in press.
• 47 Rohde E, Malischnik C, Thaler D. et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006; 24: 357-367.